GI
SNDX icon

GAMMA Investing’s Syndax Pharmaceuticals SNDX Stock Holding History

GAMMA Investing’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6.49K Sell
345
-72
-17% -$1.46K ﹤0.01% 3547
2026
Q2 		$9.12K Buy
417
+25
+6% +$520 ﹤0.01% 3257
2026
Q1 		$9.16K Buy
392
+112
+40% +$2.43K ﹤0.01% 3111
2025
Q4 		$5.88K Buy
280
+95
+51% +$1.66K ﹤0.01% 3214
2025
Q3 		$2.85K Buy
185
+142
+330% +$1.86K ﹤0.01% 3358
2025
Q2 		$403 Sell
43
-36
-46% -$396 ﹤0.01% 3658
2025
Q1 		$971 Sell
79
-18
-19% -$254 ﹤0.01% 3565
2024
Q4 		$1.28K Buy
97
+8
+9% +$137 ﹤0.01% 3351
2024
Q3 		$1.71K Sell
89
-1
-1% -$21 ﹤0.01% 3116
2024
Q2 		$1.85K Buy
90
+21
+30% +$439 ﹤0.01% 2901
2024
Q1 		$1.64K Buy
69
+49
+245% +$1.09K ﹤0.01% 2805
2023
Q4 		$410 Buy
+20
New +$307 ﹤0.01% 3003

Other funds holding SNDX

PRTG
Post Resch Tallon Group Pittsford, New York $146M AUM 18.19% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

GAMMA Investing's SNDX Position: Q3 2026 in Review

GAMMA Investing reduced its Syndax Pharmaceuticals (SNDX) stake by 17% in Q3 2026, selling an estimated $1.46K and leaving 345 shares worth $6.49K. The position accounts for ﹤0.01% of the portfolio, ranked #3547.

GAMMA Investing first reported a position in SNDX in Q4 2023 and has held it in 12 quarters since. The position peaked at $9.16K in Q1 2026. 5 funds tracked by Wall St. Rank hold SNDX as of Q3 2026.

  • GAMMA Investing held 345 shares of Syndax Pharmaceuticals worth $6.49K as of Q3 2026.
  • GAMMA Investing sold 72 Syndax Pharmaceuticals shares in Q3 2026, an estimated $1.46K.
  • Syndax Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3547 holding.
  • GAMMA Investing first reported a position in Syndax Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
  • GAMMA Investing's Syndax Pharmaceuticals position peaked at $9.16K in Q1 2026.
  • 5 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.